ENDRA Life Sciences Inc. (NDRA) is a publicly traded company in the Unknown sector. Across all available filings, 12 corporate insiders have executed 84 transactions totaling $1.2M, demonstrating a bearish sentiment with -$586.0K in net insider flow. The most recent transaction on Jan 21, 2026 involved a transaction of 75,000 shares valued at $0.
No significant insider buying has been recorded for NDRA in the recent period.
No significant insider selling has been recorded for NDRA in the recent period.
Based on recent SEC filings, insider sentiment for NDRA is bearish with an Insider Alignment Score of 26/100 and a net flow of -$586.0K. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at ENDRA Life Sciences Inc. (NDRA) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 12 insiders are actively trading NDRA stock, having executed 84 transactions in the past 90 days. The most active insider is Anthony Digiandomenico (Executive), who has made 12 transactions totaling $919.0K.
Get notified when executives and directors at NDRA file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Jan 21, 2026 | Y. Tokman Alexander | Executive | Award | 75,000 | $N/A | $0 | |
| Jan 21, 2026 | Basenese Lou | Executive | Award | 60,324 | $N/A | $0 | |
| Jan 21, 2026 | Jacroux Richard | Chief Financial Officer | Award | 20,000 | $N/A | $0 | C-Suite |
| Jan 21, 2026 | Harsh Michael | Executive | Award | 60,324 | $N/A | $0 | |
| Jan 21, 2026 | Digiandomenico Anthony | Executive | Award | 60,324 | $N/A | $0 | |
| Oct 10, 2025 | Digiandomenico Anthony | Executive | Award | 70,822 | $7.06 | $500.0K | Large |
| Jun 11, 2025 | Digiandomenico Anthony | Executive | Award | 5,384 | $N/A | $0 | |
| Jun 11, 2025 | Harsh Michael | Executive | Award | 5,384 | $N/A | $0 | |
| Jun 11, 2025 | Basenese Lou | Executive | Award | 5,384 | $N/A | $0 | |
| Aug 27, 2024 | Ag Ubs Group | Executive | Purchase | 3,715 | $0.55 | $2.0K | |
| Aug 27, 2024 | Ag Ubs Group | Executive | Purchase | 0 | $N/A | $0 | |
| May 18, 2023 | Milos Thornton Michael | Executive | Purchase | 15,000 | $1.65 | $24.8K | |
| May 2, 2023 | Digiandomenico Anthony | Executive | Purchase | 83,333 | $1.20 | $100.0K | |
| Dec 9, 2022 | Milos Thornton Michael | Executive | Purchase | 1,500 | $3.40 | $5.1K | |
| Nov 23, 2022 | Y. Tokman Alexander | Executive | Purchase | 10,000 | $0.17 | $1.7K |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 18 | $893.1K | 39.0% |
Award(A) | 22 | $587.4K | 25.7% |
Conversion(C) | 11 | $379.8K | 16.6% |
Purchase(P) | 28 | $307.1K | 13.4% |
Exercise (Options)(X) | 5 | $121.3K | 5.3% |
Insider selling pressure at ENDRA Life Sciences Inc. has increased, with 12 insiders executing 84 transactions across all time. Total sales of $893.1K significantly outpace purchases of $307.1K, resulting in a net outflow of $586.0K. This selling activity appears largely discretionary, which may warrant closer attention from investors.